Summary
Salmon calcitonin has been used for the management of acute hypercalcemia for the past several years. Unlike other hypocalcemic agents, it is effective within 2 hours after first dosing. This pharmacologic agent shows peak effect at 24–48 hours and has a duration of action of 4–7 days in most cases. Its effectiveness may diminish thereafter despite continuous administration (the so-called “escape phenomenon”). Salmon calcitonin has been shown to be effective in the management of acute hypercalcemia due to a variety of causes, and, because of its low toxicity profile, it may be administered to patients with congestive heart failure or azotemia. Salmon calcitonin is also an analgesic agent in patients with pain associated with bone metastases and may be used in conjunction with other hypocalcemic agents such as mithramycin, the bisphosphonates, or gallium nitrate to prolong the clinical response to more than 1 week. Salmon calcitonin is therefore effective and safe in the management of acute hypercalcemia.
Similar content being viewed by others
References
Copp DH, Cameron EC, Cheney BA, et al.: Evidence for calcitonin: a new hormone from the parathyroid that lowers blood calcium.Endocrinology 1962;70:638–649
Tepperman J:Metabolic and Endocrine Physiology, 3rd ed. Chicago: Year Book Medical Publishers; 1973, pp. 227–229
Talmage RV, Cooper CW, Toverud SU: The physiological significance of calcitonin. In: Peck WA (ed):Bone and Mineral Research, Annual 1. Amsterdam: Excerpta Medica; 1983, pp. 74–143
de Luise M, Martin TJ, Melick RA: Inactivation and degradation of porcine calcitonin by rat liver and relative stability of salmon calcitonin.J Endocrinol 1970;48:181–188
Fillastre JP, Humbert G, Leroy J, Maitrot J, Deshayes P, Canonne MA: Furosemide, mithramycin, and salmon calcitonin in hypercalcemia.Eur J Intensive Care Med 1975;1:185–188
Wisneski LA, Croom WP, Silva OL, Becker KL, et al: Salmon calcitonin in hypercalcemia.Clinical Pharmacol Ther 1978;24:219–222
Adachi I, Kimura S, Yamaguchi K, Suzuki M, Abe K: Synthetic salmon calcitonin as an antihypercalcemic agent for hypercalcemia in malignancy.Gan To Kaguku Ryoho 1986; 13:2637–2644
Au WYW: Calcitonin treatment of hypercalcemia due to parathyroid carcinoma: synergistic effect of prednisone on long-term treatment of hypercalcemia.Arch Intern Med 1975;135:1594–1597
Deftos LJ, Neer R: Medical management of the hypercalcemia of malignancy.Ann Rev Med 1974;25:323–330
Stevenson JC: Current management of malignant hypercalcemia.Drugs 1988;36:229–239
Caulin F: Personal communication, Rorer International, 1989
Raisz LG, Trummel CL, et al.: Effect of glucocorticoids on bone resorption in tissue culture.Endocrinology 1972;90:961–967
Bilezikian J: Etiologies and therapy of hypercalcemia.Endocrinol Metab Clin North Am 1989;18:408
Binstock MI, Mundy GR: Effect of calcitonin and glucosteroids in combination on the hypercalcemia of malignancy.Ann Intern Med 1980;93:269–271
Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT: Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.Lancet 1985;ii:907–910
Ralston SH, Alzaid AA, Gardner MD, Boyle IT: Treatment of cancer-associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.Br Med J 1986;292:1549–1550
Junghall S, Rastad J, Akerstrom G: Comparative effects of calcitonin and clodronate in hypercalcaemia.Bone 1987;8 (Suppl. 1):S79-S83
Warrell RP, et al.: Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose-response analysis.Cancer Res 1986;46:4208–4212
Warrell RP, Israel R, Frisone M, Snyder T, Gaynor JJ, Bockman RS: Gallium nitrate for acute treatment of cancer-related hypercalcemia: a randomized double-blind comparison to calcitonin.Ann Intern Med 1988;108(5):669–674
Thiebaud D, Burckhardt P, Jaeger P, Azria M: Effectiveness of salmon calcitonin administered as suppositories in tumor-induced hypercalcemia.Am J Med 1987;82(4):745–750
Wallach S: Treatment of Paget's disease. In:Advances in Internal Medicine, Vol. 27. Chicago, Year Book Medical Publishers, 1982; pp. 1–43
Hamilton Jr CR: Effects of synthetic salmon calcitonin in patients with Paget's disease of bone.Am J Med 1974;56: 315–322
Silva OL, Becker KL: Salmon calcitonin in the treatment of hypercalcemia.Arch Intern Med 1973;132:337–339
Hindley AC, Hill EB, Leyland MJ, Wiles AE: A double-blind controlled trial of salmon calcitonin in pain due to malignancy.Cancer Chemother Pharmacol 1982;9:71–74
Gennari C, Chierichetti SM, Piolini M, Vibelli C, Agnusdei D, Civitelli R, et al.: Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study.Curr Ther Res 1985;38:298–308
Szanto J, Jozsef S, Rado J, Juhos E, Hindy I, Eckhardt S: Pain killing with calcitonin in patients with malignant tumours.Oncology 1986;43:69–72
Roth A, Kolaric K: Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer.Oncology 1986;43:283–287
Serdengecti S, Serdengecti K, Derman U, Berkarda B: Salmon calcitonin in the treatment of bone metastases.Int J Clin Pharm Res 1986;6:151–155
Schiraldi GF, Soresi E, Locicero S, Harari S, Scoccia S: Salmon calcitonin in cancer pain: comparison between two different treatment schedules.Int J Clin Pharmacol Ther Toxicol 1987;25:229–232
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wisneski, L.A. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 46 (Suppl 1), S26–S30 (1990). https://doi.org/10.1007/BF02553290
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02553290